Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study shows economic benefit of EECP (enhanced external counterpulsation):

This article was originally published in Clinica

Executive Summary

Use of Vasomedical's enhanced external counterpulsation (EECP) therapy in patients with chronic, refractory angina results in a significant reduction in the number of inpatient hospital days in the first year after treatment, according to an Irish study presented at the British Cardiac Society meeting in May. The study was the first to demonstrate an economic benefit of EECP. Data from a US study presented at the same meeting supported the use of EECP as initial treatment in patients with angina or chest pain.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071448

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel